Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
Radiother Oncol ; 189: 109916, 2023 12.
Article in English | MEDLINE | ID: mdl-37739316

ABSTRACT

PURPOSE: Radiation-induced meningiomas (RIM) are the most common secondary neoplasm post cranial radiotherapy, yet optimal surveillance and treatment strategies remain contentious. Herein, we report the clinical outcomes and radiological growth rate of RIM, diagnosed in a cohort of survivors undergoing MRI screening, with the objective of informing clinical guidelines and practice. MATERIALS AND METHODS: Long-term survivors of paediatric or young-adult malignancies, diagnosed with RIM between 1990 and 2015, were identified. Absolute (AGR) and relative (RGR) volumetric growth rates were calculated. Rapid growth was defined as AGR > 2 cm3/year or AGR > 1 cm3/year and RGR ≥ 30% RESULTS: Fifty-two patients (87 RIM) were included. Median age at first RIM diagnosis was 33.9 (range,13.8-54.1) years. Seventy-seven (88%) RIM were asymptomatic at detection. Median follow-up time from first RIM detection was 11 (range, 0.6-28) years. Median absolute and relative volumetric growth rates were 0.05 (IQR 0.01-0.11) cm3 and 26 (IQR 7-79) % per year, respectively. Two (3.3%) RIM demonstrated rapid growth. Active surveillance was adopted for 67 (77%) RIM in 40 patients. Neurological sequelae due to RIM progression were reported in 5% of patients on active surveillance. Surgery was performed for 33 RIM (30 patients): 18 (54.5%) at diagnosis and 15 (45.5%) after active surveillance. Histopathology was WHO Grade 1 (85.2%), 2 (11.1%), 3 (3.7%). Following resection, 10-year local recurrence rate was 12%. During follow-up, 19 (37%) survivors developed multiple RIM. CONCLUSIONS: Asymptomatic RIM are typically low-grade tumours which exhibit slow growth. Active surveillance appears to be a safe initial strategy for asymptomatic RIM, associated with a low rate of neurological morbidity.


Subject(s)
Meningeal Neoplasms , Meningioma , Humans , Young Adult , Child , Adolescent , Adult , Middle Aged , Meningioma/radiotherapy , Meningioma/surgery , Watchful Waiting , Retrospective Studies , Survivors , Disease Progression
2.
Oper Neurosurg (Hagerstown) ; 22(4): 208-214, 2022 04 01.
Article in English | MEDLINE | ID: mdl-35234410

ABSTRACT

BACKGROUND: Postoperative stereotactic radiosurgery after resection of brain metastases is currently the standard of care. However, rates of leptomeningeal disease (LMD) after postoperative stereotactic radiosurgery have been reported to be >30%. Neoadjuvant stereotactic radiosurgery (NaSRS) has been proposed as an alternative treatment approach to decrease this risk. OBJECTIVE: To report the local control (LC) and LMD rates in patients undergoing NaSRS. METHODS: Our retrospective multicenter case series included consecutive patients planned for SRS followed by resection of intracranial lesions with a confirmed primary malignancy. Concurrent SRS alone to other intracranial lesions was permitted. Exclusion criteria included previous local treatment to that particular lesion and Eastern Cooperative Oncology Group performance status ≥3. Outcomes reported included LC, distant intracranial control (DC), overall survival, LMD, and radionecrosis (RN) rates. RESULTS: Overall, 28 patients with 29 lesions were eligible for analysis. The median follow-up was 12.8 months. The mean age was 62.5 (range 43-80) years, and 55% were Eastern Cooperative Oncology Group performance status 0 to 1. The most common primary malignancies included non-small cell lung cancer (43%) and melanoma (32%). Hypofractionated SRS was used in 62.1%. The 12-month LC and LMD rates were 91.3% and 4.0%, respectively. The 12-month RN, DC, and overall survival rates were 5.0%, 51.5%, and 60.1%, respectively. CONCLUSION: Compared with postoperative SRS, our study suggests that NaSRS leads to comparable local control with a decreased risk of LMD and RN. This is the first NaSRS series with a majority of patients treated with fractionated SRS. NaSRS is a promising approach for appropriate patients where surgical resection is a component of local therapy.


Subject(s)
Brain Neoplasms , Carcinoma, Non-Small-Cell Lung , Lung Neoplasms , Meningeal Neoplasms , Radiosurgery , Adult , Aged , Aged, 80 and over , Brain Neoplasms/pathology , Brain Neoplasms/radiotherapy , Brain Neoplasms/surgery , Carcinoma, Non-Small-Cell Lung/secondary , Carcinoma, Non-Small-Cell Lung/surgery , Humans , Lung Neoplasms/radiotherapy , Lung Neoplasms/surgery , Meningeal Neoplasms/surgery , Middle Aged , Neoadjuvant Therapy/adverse effects , Radiosurgery/adverse effects , Retrospective Studies , Treatment Outcome
3.
Curr Oncol Rep ; 21(8): 73, 2019 07 04.
Article in English | MEDLINE | ID: mdl-31270629

ABSTRACT

PURPOSE OF REVIEW: Recent randomized evidence has supported the use of resection followed by stereotactic radiosurgery (SRS) as standard of care for patients with a limited number of brain metastases. However, there are known toxicities, including a relatively high incidence of leptomeningeal disease. Neoadjuvant SRS has been proposed to minimize these potential sequalae. This review summarizes the current data and principles for neoadjuvant SRS. RECENT FINDINGS: Recently published studies have demonstrated neoadjuvant SRS to be feasible and to achieve similar oncological outcomes to postoperative SRS. A decreased incidence of leptomeningeal disease and radionecrosis has been observed. Additionally, neoadjuvant SRS can improve accuracy of target volume delineation and decrease the volume of irradiated normal tissue. Neoadjuvant SRS has emerged as a promising sequencing management approach. Its main advantages appear to be in reduction of toxicity. Ongoing trials will further explore this treatment method and establish which patients will benefit most from this technique.


Subject(s)
Brain Neoplasms/radiotherapy , Brain Neoplasms/secondary , Radiosurgery , Humans , Meningeal Neoplasms/etiology , Neoadjuvant Therapy/adverse effects , Radiation Injuries/etiology , Radiosurgery/adverse effects , Treatment Outcome , Tumor Burden
4.
J Clin Neurosci ; 15(3): 313-6, 2008 Mar.
Article in English | MEDLINE | ID: mdl-18191572

ABSTRACT

This paper is a case report of Terson's Syndrome (TS) in spontaneous spinal subarachnoid haemorrhage (SAH). A 66-year-old woman with acute onset of severe back pain was transferred to our institution for management of her sciatica. The presence of an intraretinal haemorrhage alerted us to consider intracranial SAH, but investigations showed no intracranial source. Eventually, the patient was diagnosed with a thoracic spinal SAH. The patient's symptoms gradually improved with conservative management but within 1 month she had a recurrence. A spinal and CT angiogram did not elicit the aetiology. The diagnosis of spontaneous spinal SAH can be difficult. The recognition of TS has important prognostic implications, often heralding subarachnoid rebleeding. Fundoscopic examination appears mandatory as a tool for diagnosis and regular non-invasive monitoring of patients with SAH.


Subject(s)
Retinal Hemorrhage/etiology , Subarachnoid Hemorrhage/complications , Vitreous Hemorrhage/etiology , Aged , Female , Humans , Magnetic Resonance Imaging , Retinal Hemorrhage/pathology , Subarachnoid Hemorrhage/pathology , Syndrome , Tomography, X-Ray Computed , Vitreous Hemorrhage/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...